Silence Therapeutics plc (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $33.83.

Several research firms have weighed in on SLN. Chardan Capital lowered their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 7th. The Goldman Sachs Group lowered their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a report on Friday, May 9th. BMO Capital Markets lowered their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Finally, Morgan Stanley lowered their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, May 9th.

Silence Therapeutics Stock Performance

NASDAQ SLN opened at $5.24 on Friday. The stock has a market capitalization of $156.83 million, a P/E ratio of -3.34 and a beta of 1.41. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $22.47. The business’s fifty day moving average is $4.00 and its two-hundred day moving average is $4.98.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.58 million. On average, research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at $26,000. Barclays PLC lifted its position in Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares during the last quarter. Jump Financial LLC acquired a new position in Silence Therapeutics during the 1st quarter worth $74,000. Finally, Ameriprise Financial Inc. acquired a new position in Silence Therapeutics during the 4th quarter worth $113,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.